Bayer announced today that data from across the KERENDIA® (finerenone) comprehensive clinical trial program will be presented at the Heart Failure Society of America (HFSA)’s Annual Scientific Meeting ...
The European Society of Cardiology has recently published guidelines regarding the management of pericarditis and myocarditis.
On 15 September 2025, Regeneron Pharmaceuticals conducted a study is researching an experimental drug called REGN5381 (called ...
Ongoing research and sustained efforts are creating optimism for more effective therapies and the possibility of a cure.
This case highlights the diagnostic value of Holter ECG monitoring in uncovering spontaneous arrhythmia mechanisms. Several ...
Cardiovascular disease is a silent killer and a worldwide threat. According to the World Health Organization, 17-18 million ...
A randomized trial of in-hospital initiation of an SGLT2 inhibitor in patients with heart failure missed its endpoint, but a ...
ASX healthcare sector struggling to find relief after weeks of weakness but Morgans’ Scott Power reckons it might finally be ...
Cardiac rehabilitation is a crucial, underutilized service for heart attack survivors, offering structured exercise programs ...
The Chosun Ilbo on MSN
Resting heart rate over 80 doubles obesity risk
Have you ever checked your own pulse? Do you know your resting heart rate? Understanding your pulse or heart rate can greatly ...
26d
Common heart attack drug doesn’t work and may raise risk of death for some women, new studies say
Beta-blockers, the gold standard drug treatment for heart attacks, is ineffective for many and may increase the risk of death and disability in certain women, new studies find.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback